Improvement Upon a Multi-Residue Method for Nitrosamine Analysis in Losartan Drug Product Using an Enhanced LC/MS/MS System
Posters | 2023 | Agilent Technologies | ASMSInstrumentation
LC/MS, LC/MS/MS, LC/QQQ
IndustriesPharma & Biopharma
ManufacturerAgilent Technologies
Key wordsnitrosamine, nmor, responses, nmea, npyr, npip, ndpa, ndea, ndma, ndba, losartan, concentration, acquisition, drug, impurities, min, time, nitrosodi, diverter, counts, abundance, apci, injectionto, spiked, api, were, compounds, concentrations, relative, nmda, potassium, temperature, matrix, classifying, nitrosomethylethylamine, nitrosomorpholine, polarity, nitrosopyrrolidine, carcinogens, nitrosopiperidine, high, fragile, cohort, supernatants, butylamine, cav, low, blocker, nitrosodiethylamine, genotoxic
Similar PDF
Determination of Nitrosamine Impurities Using the Agilent 6475 Triple Quadrupole LC/MS System
2023|Agilent Technologies|Applications
Application Note Pharma/Biopharma Determination of Nitrosamine Impurities Using the Agilent 6475 Triple Quadrupole LC/MS System Authors Linfeng Wu and Lee Bertram Agilent Technologies, Inc. Santa Clara, CA, U.S. Shan-An Chan Agilent Technologies, Inc. Taiwan Abstract Nitrosamine impurities are by-products that…
Key words
nitrosamine, nitrosaminenmor, nmorresponses, responsesndma, ndmanmea, nmeanpyr, npyrnpip, npipndpa, ndpandba, ndbandea, ndeacounts, countsconcentration, concentrationlosartan, losartanblocker, blockerdrug
Determination of Nitrosamine Impurities Using the Agilent 6495D Triple Quadrupole LC/MS System
2023|Agilent Technologies|Applications
Application Note Determination of Nitrosamine Impurities Using the Agilent 6495D Triple Quadrupole LC/MS System Authors Abstract Lee Bertram and Linfeng Wu Agilent Technologies, Inc. Nitrosamine impurities are byproducts produced in trace amounts during the manufacture of pharmaceutical drugs. These impurities…
Key words
fragile, fragilenitrosamine, nitrosaminenpyr, npyrnmor, nmorresponses, responsesndma, ndmanmea, nmeanpip, npipndpa, ndpandba, ndbandea, ndealosartan, losartandrug, drugacquisition, acquisitionmin
Determination of Nitrosamines in Active Pharmaceutical Ingredients
2020|Agilent Technologies|Applications
Application Note Pharmaceutical Determination of Nitrosamines in Active Pharmaceutical Ingredients High flexibility and performance at lowest cost using the Agilent 1260 Infinity II Prime LC with the Agilent Ultivo LC/TQ for LC/MS analysis Author Edgar Naegele Agilent Technologies, Inc. Abstract…
Key words
accuracy, accuracynitrosamine, nitrosaminendba, ndbanitrosamines, nitrosaminesnmor, nmornmea, nmeandpa, ndpandea, ndeaultivo, ultivondma, ndmanpip, npipvalsartan, valsartanpharmaceutical, pharmaceuticalgti, gtinitroso
Determination of Nitrosamine Impurities Using the Ultivo Triple Quadrupole LC/MS
2019|Agilent Technologies|Applications
Application Note Pharmaceuticals Determination of Nitrosamine Impurities Using the Ultivo Triple Quadrupole LC/MS Detection of regulated genotoxic impurities from the drug manufacturing process Authors Chander Mani and Saikat Banerjee Agilent Technologies, Inc. Abstract Recent findings show that some Angiotensin II…
Key words
nmipa, nmipanmpha, nmphaethylnitrosamine, ethylnitrosaminenmba, nmbaneipa, neipandipa, ndipandba, ndbandea, ndeanmea, nmeanpyr, npyrnpip, npipndma, ndmaultivo, ultivonitrosamine, nitrosamineaverage